HK1183693A1 - Methods for treating eye disorders - Google Patents

Methods for treating eye disorders

Info

Publication number
HK1183693A1
HK1183693A1 HK13111114.3A HK13111114A HK1183693A1 HK 1183693 A1 HK1183693 A1 HK 1183693A1 HK 13111114 A HK13111114 A HK 13111114A HK 1183693 A1 HK1183693 A1 HK 1183693A1
Authority
HK
Hong Kong
Prior art keywords
methods
eye disorders
treating eye
treating
disorders
Prior art date
Application number
HK13111114.3A
Other languages
English (en)
Chinese (zh)
Inventor
．法因施泰因
．艾伯特
．梅特
．巴-伊蘭
．斯皮瓦克
．卡林斯基
．斯拉格爾
Original Assignee
夸克製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 夸克製藥公司 filed Critical 夸克製藥公司
Publication of HK1183693A1 publication Critical patent/HK1183693A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
HK13111114.3A 2008-10-22 2013-09-27 Methods for treating eye disorders HK1183693A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19699508P 2008-10-22 2008-10-22
US19893108P 2008-11-11 2008-11-11
IL2009000179 2009-02-15

Publications (1)

Publication Number Publication Date
HK1183693A1 true HK1183693A1 (en) 2014-01-03

Family

ID=54839547

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13111114.3A HK1183693A1 (en) 2008-10-22 2013-09-27 Methods for treating eye disorders
HK16100198.2A HK1212883A1 (zh) 2008-10-22 2016-01-08 治療眼部疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16100198.2A HK1212883A1 (zh) 2008-10-22 2016-01-08 治療眼部疾病的方法

Country Status (16)

Country Link
US (4) US8765931B2 (es)
EP (1) EP2350279B1 (es)
JP (1) JP5592892B2 (es)
KR (1) KR101672563B1 (es)
CN (3) CN102994500B (es)
AU (1) AU2009308380B2 (es)
CA (2) CA2738957A1 (es)
DK (1) DK2350279T3 (es)
EA (1) EA022418B1 (es)
ES (1) ES2563984T3 (es)
HK (2) HK1183693A1 (es)
IL (1) IL212986A (es)
NZ (1) NZ591391A (es)
PL (1) PL2350279T3 (es)
SI (1) SI2350279T1 (es)
WO (1) WO2010048352A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2293800B1 (en) * 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
CN102994500B (zh) * 2008-10-22 2015-04-01 夸克制药公司 治疗眼部疾病的方法
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
ES2599986T3 (es) * 2009-08-11 2017-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
AU2010324658A1 (en) 2009-11-26 2012-05-03 Quark Pharmaceuticals, Inc. siRNA compounds comprising terminal substitutions
WO2012006083A2 (en) * 2010-07-09 2012-01-12 University Of Florida Research Foundation, Inc. Targeted receptor-mediated sirna
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
AU2012332517B9 (en) 2011-11-03 2017-08-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
CA2858627C (en) * 2012-01-04 2020-12-01 Quark Pharmaceuticals, Inc. Double-stranded rna compounds to casp2 and uses thereof
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014043289A2 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
EP2895608B1 (en) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
WO2014050301A1 (ja) * 2012-09-27 2014-04-03 千寿製薬株式会社 水性液剤
CN105209619B (zh) * 2013-03-11 2018-10-12 泰莱托恩基金会 miR-204和miR-211及其用途
KR102234620B1 (ko) 2013-03-14 2021-04-05 알닐람 파마슈티칼스 인코포레이티드 보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
AU2015207773B2 (en) 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
MA44908A (fr) 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
CA3036093A1 (en) * 2016-09-09 2018-03-15 Cornell University Delivery of nucleic acids, proteins, and small molecules in vitreous vesicular bodies
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2018083607A1 (en) * 2016-11-02 2018-05-11 Friedrich Miescher Institute For Biomedical Research Synp198, a promoter for the specific expression of genes in direction selective retinal ganglion cells
RU2633349C1 (ru) * 2016-11-24 2017-10-11 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ определения дифференцированных показаний к срокам лечения нарушений прекорнеальной слезной пленки после лазерного in situ кератомилеза с фемтолазерным сопровождением у детей
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
RU2643579C1 (ru) * 2017-03-29 2018-02-02 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемической нейропатии зрительного нерва карбамилированным дарбэпоэтином в эксперименте
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
CN110604811B (zh) * 2018-06-14 2023-01-31 陕西慧康生物科技有限责任公司 含有重组人溶菌酶和重组人表皮生长因子的人工泪液
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
EP3840785A4 (en) * 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBERIAN OPTIC ATROPHY
EP3852608A4 (en) 2018-09-21 2022-09-28 Aufbau Medical Innovations Limited COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA
BR102020023560A8 (pt) * 2019-11-19 2023-02-07 Johnson & Johnson Consumer Inc Composições e métodos para tratar os olhos
CN113025633A (zh) 2019-12-09 2021-06-25 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN112063624A (zh) * 2020-09-19 2020-12-11 湖南中医药大学 一种抑制caspase 1基因表达的siRNA分子及其应用
AU2022261359A1 (en) 2021-04-19 2023-10-12 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
WO2023014654A2 (en) * 2021-08-02 2023-02-09 University Of Massachusetts Oligonucleotides for htt-1a modulation
AR127477A1 (es) 2021-10-29 2024-01-31 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251666B1 (en) * 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
AU2001289068A1 (en) * 2000-09-20 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 2 expression
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
CA2465860A1 (en) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
DK3222724T3 (en) * 2002-08-05 2018-12-03 Silence Therapeutics Gmbh ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES
KR20050098954A (ko) * 2003-03-05 2005-10-12 세네스코 테크놀로지스 인코포레이티드 이아이에프-5에이1의 발현을 억제하기 위한 안티센스올리고뉴클레오타이드 또는 에스아이알엔에이의 이용
EP1626732B1 (en) * 2003-05-22 2013-04-03 CHIESI FARMACEUTICI S.p.A. Means for preventing and treating cellular death and their biological applications
FR2855054B1 (fr) * 2003-05-22 2005-07-08 Theraptosis Moyens pour bloquer ou retarder une mort cellulaire in vitro
EP1791568B1 (en) * 2004-08-16 2012-08-15 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
AU2008306455C1 (en) * 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures
CN102994500B (zh) * 2008-10-22 2015-04-01 夸克制药公司 治疗眼部疾病的方法

Also Published As

Publication number Publication date
CN104857526A (zh) 2015-08-26
CN102994500B (zh) 2015-04-01
IL212986A (en) 2016-05-31
CA2962219C (en) 2020-08-25
IL212986A0 (en) 2011-07-31
US9701961B2 (en) 2017-07-11
WO2010048352A3 (en) 2010-06-17
ES2563984T3 (es) 2016-03-17
EP2350279A2 (en) 2011-08-03
DK2350279T3 (en) 2016-02-15
WO2010048352A2 (en) 2010-04-29
US20110229557A1 (en) 2011-09-22
KR101672563B1 (ko) 2016-11-03
CN102449151A (zh) 2012-05-09
CN104857526B (zh) 2019-03-05
SI2350279T1 (sl) 2016-04-29
WO2010048352A8 (en) 2011-08-11
US20150050328A1 (en) 2015-02-19
CA2962219A1 (en) 2010-04-29
JP2012506450A (ja) 2012-03-15
CN102994500A (zh) 2013-03-27
HK1212883A1 (zh) 2016-06-24
EP2350279B1 (en) 2016-01-27
AU2009308380B2 (en) 2015-05-28
CA2738957A1 (en) 2010-04-29
KR20110081826A (ko) 2011-07-14
NZ591391A (en) 2012-10-26
US20170306329A1 (en) 2017-10-26
AU2009308380A1 (en) 2010-04-29
US8765931B2 (en) 2014-07-01
EA022418B1 (ru) 2015-12-30
US20150361430A1 (en) 2015-12-17
PL2350279T3 (pl) 2016-05-31
JP5592892B2 (ja) 2014-09-17
US9121020B2 (en) 2015-09-01
EA201170551A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
HK1212883A1 (zh) 治療眼部疾病的方法
IL257418A (en) Methods for treating addiction
WO2010144865A9 (en) Methods for treating gastrointestinal disorders
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
EP2331088A4 (en) COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
IL212348A0 (en) Treatment method
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
GB2467710B (en) Methods for treating social disorders
EP2323681A4 (en) METHODS OF TREATING VIRAL CONDITIONS
EP2365747A4 (en) METHODS OF TREATING GASTROINTESTINAL DISEASES
HUE045869T2 (hu) Módszerek hajhullásos rendellenességek kezelésére
EP2307035A4 (en) TREATMENT OF EPILEPSY
HK1203516A1 (en) Methods for treating psoriasis
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
EP2477635A4 (en) METHODS OF TREATING CEREBRAL TUMORS
EP2296682B8 (en) Methods of treating ophthalmic disorders
ZA201009226B (en) Nifurtimox for treating disease caused by trichomonadida
EP2249837A4 (en) METHOD FOR TREATING THROMBOEMBOLIC ILLNESSES
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
SG175106A1 (en) Method for treating immune disorders
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS
IL207906A0 (en) Treatment for ocular-related disorders
EP2496080A4 (en) METHOD FOR THE TREATMENT OF MORBUS PARKINSON